Healthcare leaders are supporting the Biden-Harris Administration’s plan to expand coverage of GLP-1 medications for Medicare and Medicaid patients, including those seeking treatment for obesity. Currently, these medications are covered for diabetes but not for weight loss by Medicare, and only 13 state Medicaid programs offer coverage. The proposal could benefit millions of patients by reducing out-of-pocket costs and improving access to obesity treatment. Advocates hope the incoming administration will support the rule, despite potential opposition. With obesity affecting 42% of Americans, comprehensive coverage of these medications is seen as crucial for improving public health outcomes.
Source link
Health Leaders Applaud Biden’s Proposal to Expand Medicare/Medicaid Coverage for Anti-Obesity Medications
